The UC Davis Department of Neurology has an outstanding Movement Disorders Program that provides both inpatient and outpatient evaluation, treatment, and management of a range of diseases that cause involuntary excessive movements or slow, awkward, deliberate movements. Our experts are also actively engaged in both clinical and basic research to develop new and more effective treatments as well as to seek cures for these disorders.
Faculty members in the Department of Neurology provide diagnosis and management of movement disorders such as:
- Parkinson's disease
- Huntington's disease
- Essential tremor
- Several other movement disorders
In addition to a daily movement disorders outpatient clinic, we also offer a weekly Huntington's disease specialty clinic on Fridays in our Huntington's Disease Center of Excellence.
Our patients come from Northern California as well as neighboring states to receive the latest treatments, which include:
- Oral medication
- Botulinum toxin therapy
- Deep Brain Stimulation (DBS) implantation and programming
In addition to patient care, our faculty members conduct both basic and clinical research aimed at developing new treatments for Parkinson’s disease, Huntington’s disease, and other movement disorders. (For more information about our research into Huntington's disease, please visit our HD Center of Excellence Research page.)
Some of our faculty conduct clinical trials as members of the Parkinson Study Group, an organization of researchers from the U.S. and Canada who are working to test new treatments for PD, as well as looking into the genetics of people who may be predisposed to develop it. Patients who would like to help in our ongoing research efforts may be able to participate in one of several clinical studies designed to improve medical knowledge about these conditions and to test potential new therapies. Current studies are described below:
Effect of LY3154207 on Cognitive in Mild-to-Moderate Parkinson's Disease Dementia (PDD)
For more information, enter NCT03305809 into the search box at www.clinicaltrials.gov.
A Ramdonmized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, and Clinical and Exploratory Biologigical Activity of the Chronic Administration of Nilotinib in Participants with Parkinson's Disease (PD)
For more information, enter NCT03205488 into the search box at www.clinicaltrials.gov.
A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients
For more information, enter NCT02605434 into the search box at www.clinicaltrials.gov.
Network Level Effects of vSTN Theta Frequency DBS on Cognition in PD
Preliminary Sensor Design and Data Gathering for Robotic Exoskeleton-Based Attenuation of Essential Tremor